Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy

International Archives of Allergy and Immunology

Volumn 158, Issue 2, 2012, Pages 157-167

  Bordas Le Floch, Véronique ^a   Bussières, Laetitia ^a   Airouche, Sabi ^a   Lautrette, Aurélie ^a   Bouley, Julien ^a   Berjont, Nathalie ^a   Horiot, Stéphane ^a   Huet, Axelle ^a   Jain, Karine ^a   Lemoine, Pierrick ^a   Chabre, Henri ^a   Batard, Thierry ^a   Mascarell, Laurent ^a   Baron Bodo, Véronique ^a   Tourdot, Sophie ^a   Nony, Emmanuel ^a   Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

Author keywords

Allergy vaccine; Der p 2 molecules; House dust mite; Recombinant allergen

Indexed keywords

HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; RECOMBINANT ALLERGEN; RECOMBINANT DER P 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN ANTIBODY REACTION; ARTICLE; BASOPHIL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DISULFIDE BOND; ESCHERICHIA COLI; IMMUNOTHERAPY; ION EXCHANGE CHROMATOGRAPHY; MOUSE; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TEMPERATURE STRESS; THERMOSTABILITY;

ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ARTHROPOD PROTEINS; ASTHMA; BASOPHILS; CD4-POSITIVE T-LYMPHOCYTES; DESENSITIZATION, IMMUNOLOGIC; ESCHERICHIA COLI; IMMUNOGLOBULIN E; MICE; MICE, INBRED BALB C; PICHIA; RECOMBINANT PROTEINS;

EID: 84856185013     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000331143     Document Type: Article

References (55)

1. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T, Akhanda W, Almarales RC, Ansotegui I, Bonifazi F, Ceuppens J, Chivato T, Dimova D, Dumitrascu D, Fontana L, Katelaris CH, Kaulsay R, Kuna P, Larenas-Linnemann D, Manoussakis M, Nekam K, Nunes C, O'Hehir R, Olaguibel JM, Onder NB, Park JW, Priftanji A, Puy R, Sarmiento L, Scadding G, Schmid-Grendelmeier P, Seberova E, Sepiashvili R, Sole D, Togias A, Tomino C, Toskala E, Van Beever H, Vieths S: Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 2009; 64(suppl 91):1-59.
2. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, Andre C, de Beaumont O, Melac M: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338-1345. (Pubitemid 350225683)
3. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118: 434-440. (Pubitemid 44160721)
4. Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4-12.
5. Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW: Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004; 93: 3-12.
6. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-256. (Pubitemid 34158289)
7. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562.
8. Pichler CE, Helbling A, Pichler WJ: Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001; 56: 301-306. (Pubitemid 32222609)
9. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, Le Gall M: Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123: 160-166.
10. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138.
11. Valenta R, Niederberger V: Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007; 119: 826-830. (Pubitemid 46527833)
12. Egger M, Hauser M, Himly M, Wopfner N, Wallner M, Ferreira F: Development of recombinant allergens for diagnosis and therapy. Front Biosci 2009; 1: 77-90.
13. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, Mothes N, Spitzauer S, Montagut A, Galvain S, Melac M, Andre C, Poulsen LK, Malling HJ: Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122: 951-960.
14. Pauli G, Malling HJ: The current state of recombinant allergens for immunotherapy. Curr Opin Allergy Clin Immunol 2010; 10: 575-581.
15. Asturias JA: Recombinant hypoallergens for immunotherapy of Parietaria judaica pollen allergy. Front Biosci 2009; 14: 4606-4617.
16. Thomas WR, Hales BJ, Smith WA: Genetically engineered vaccines. Curr Allergy Asthma Rep 2005; 5: 197-203. (Pubitemid 40766830)
17. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61: 151-165. (Pubitemid 43381824)
18. Allam JP, Novak N, Fuchs C, Asen S, Berge S, Appel T, Geiger E, Kochan JP, Bieber T: Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003; 112: 141-148. (Pubitemid 36819819)
19. Allam JP, Wurtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, Valenta R, Wenghoefer M, Appel T, Gros E, Niederhagen B, Bieber T, Lund K, Novak N: Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 2010; 126: 638-645.
20. Allam JP, Bieber T, Novak N: Dendritic cells as potential targets for mucosal immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9: 554-557.
21. Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H, Betbeder D, Balazuc AM, Van Overtvelt L, Moingeon P: Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122: 603-609.
22. Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F, Kraft D, Valenta R: Component-resolved diagnosis of housedust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004; 34: 597-603. (Pubitemid 38534892)
23. Weghofer M, Thomas WR, Kronqvist M, Mari A, Purohit A, Pauli G, Horak F, Grönlund H, van Hage M, Valenta R, Vrtala S: Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest 2008; 38: 959-965.
24. Thomas WR, Smith W-A, Hales BJ, Mills KL, O'Brien RM: Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 2002; 129: 1-18. (Pubitemid 35316844)
25. Scala E, Alessandri C, Bernardi ML, Ferrara R, Palazzo P, Pomponi D, Quaratino D, Rasi C, Zaffiro A, Zennaro D, Mari A: Cross-sectional survey on immunoglobulin E reactivity in 23,077 subjects using an allergenic molecule-based microarray detection system. Clin Exp Allergy 2010; 40: 911-921.
26. Hales BJ, Shen H, Thomas WR: Cytokine responses to Der p 1 and Der p 7: house dust mite allergens with different IgE-binding activities. Clin Exp Allergy 2000; 30: 934-943. (Pubitemid 30427034)
27. Martínez J, Eraso E, Palacios R, Guisantes JA: Cross-reactions between Dermatophagoides pteronyssinus and Dermatophagoides farinae (Acari: Pyroglyphidae) related to the different growth phases of cultures. J Med Entomol 2000; 37: 35-39.
28. Yasueda H, Mita H, Yui Y, Shida T: Comparative analysis of physicochemical and immunochemical properties of the two major allergens from Dermatophagoides pteronyssinus and the corresponding allergens from Dermatophagoides farinae . Int Arch Allergy Appl Immunol 1989; 88: 402-407. (Pubitemid 19148011)
29. Takai T, Takaoka M, Yasueda H, Okumura K, Ogawa H: Dilution method to refold bacterially expressed recombinant Der f 2 and Der p 2 to exhibit the secondary structure and histamine-releasing activity of natural allergens. Int Arch Allergy Immunol 2005; 137: 1-8. (Pubitemid 40754716)
30. Hakkaart GA, Harmsen MM, Chua KY, Thomas WR, Aalberse RC, Van Ree R: Expression of the house dust mite allergen Der p 2 in the baker's yeast Saccharomyces cerevisiae . Clin Exp Allergy 1998; 28: 45-52. (Pubitemid 28053926)
31. Tanyaratsrisakul S, Malainual N, Jirapongsananuruk O, Smith WA, Thomas WR, Piboonpocanun S: Structural and IgE binding analyses of recombinant Der p 2 expressed from the hosts Escherichia coli and Pichia pastoris . Int Arch Allergy Immunol 2009; 151: 190-198.
32. Lienard D, Tran Dinh O, van Oort E, Van Overtvelt L, Bonneau C, Wambre E, Bardor M, Cosette P, Didier-Laurent A, de Borne FD, Delon R, van Ree R, Moingeon P, Faye L, Gomord V: Suspension-cultured BY-2 tobacco cells produce and mature immunologically active house dust mite allergens. Plant Biotechnol J 2007; 5: 93-108. (Pubitemid 46006531)
33. Smith WA, Hales BJ, Jarnicki AG, Thomas WR: Allergens of wild house dust mites: environmental Der p 1 and Der p 2 sequence polymorphisms. J Allergy Clin Immunol 2001; 107: 985-992. (Pubitemid 32523337)
34. Park JW, Kim KS, Jin HS, Kim CW, Kang DB, Choi SY, Yong TS, Oh SH, Hong CS: Der p 2 isoallergens have different allergenicity, and quantification with 2-site ELISA using monoclonal antibodies is influenced by the isoallergens. Clin Exp Allergy 2002; 32: 1042-1047. (Pubitemid 34779600)
35. Piboonpocanun S, Malainual N, Jirapongsananuruk O, Vichyanond P, Thomas WR: Genetic polymorphisms of major house dust mite allergens. Clin Exp Allergy 2006; 36: 510-516.
36. Batard T, Hrabina A, Bi XZ, Chabre H, Lemoine P, Couret M-N, Faccenda D, Villet B, Harzic P, André F, Goh SY, André C, Chew FT, Moingeon P: Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol 2006; 140:295-305. (Pubitemid 44114474)
37. Bussieres L, Bordas-Le Floch V, Bulder I, Chabre H, Nony E, Lautrette A, Berrouet C, Nguefeu Y, Horiot S, Baron-Bodo V, Van Overtvelt L, De Conti AM, Schlegel A, Maguet N, Mouz N, Lemoine P, Batard T, Moingeon P: Recombinant fusion proteins assembling Der p 1 and Der p 2 allergens from Dermatophagoides pteronyssinus . Int Arch Allergy Immunol 2010; 153: 141-151.
38. Batard T, Didierlaurent A, Chabre H, Mothes N, Bussieres L, Bohle B, Couret MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A, Clement G, Dupont F, Valent P, Krauth MT, Andre C, Valenta R, Moingeon P: Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int Arch Allergy Immunol 2005; 136: 239-249. (Pubitemid 40529195)
39. Himly M, Nony E, Chabre H, Van Overtvelt L, Neubauer A, van Ree R, Buchheit KH, Vieths S, Moingeon P, Ferreira F: Standardization of allergen products. 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation. Allergy 2009; 64: 1038-1045.
40. Yang JT, Wu CS, Martinez HM: Calculation of protein conformation from circular dichroism. Methods Enzymol 1986; 130: 208-269.
41. Burtin D, Chabre H, Olagnier B, Didierlaurent A, Couret MN, Comeau D, Wambre E, Laparra H, Van Overtvelt L, Montandon F, Batard T, Jonval V, Lorphelin A, Merle C, Berrouet C, Parry L, Gomord V, Van Ree R, Moingeon P: Production of native and modified recombinant Der p 1 molecules in tobacco plants. Clin Exp Allergy 2009; 39: 760-770.
42. Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, Van Overtvelt L, Moingeon P: Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120: 278-285. (Pubitemid 47411528)
43. Mueller GA, Benjamin DC, Rule GS: Tertiary structure of the major house dust mite allergen Der p 2: sequential and structural homologies. Biochemistry 1998; 37: 12707-12714. (Pubitemid 28433501)
44. Derewenda U, Li J, Derewenda Z, Dauter Z, Mueller GA, Rule GS, Benjamin DC: The crystal structure of a major dust mite allergen Der p 2, and its biological implications. J Mol Biol 2002; 318: 189-197. (Pubitemid 34729395)
45. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, Canonica GW: Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a metaanalysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97: 141-148. (Pubitemid 44272577)
46. Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M, Wopfner N, Thalhamer J, Achatz G: Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 2006; 5: 5-14. (Pubitemid 43796677)
47. Moingeon P: Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006; 61(suppl 81):15-19.
48. Chua KY, Huang CH, Shen HD, Thomas WR: Analysis of sequence polymorphism of a major mite allergen, Der p 2. Clin Exp Allergy 1996; 26: 829-837. (Pubitemid 26266430)
49. Lynch NR, Thomas WR, Chua Y, Garcia N, Di Prisco MC, Lopez R: In vivo biological activity of recombinant Der p II allergen of house-dust mite. Int Arch Allergy Immunol 1994; 105: 70-74. (Pubitemid 24281004)
50. Mueller GA, Smith AM, Williams DC, Jr., Hakkaart GA, Aalberse RC, Chapman MD, Rule GS, Benjamin DC: Expression and secondary structure determination by NMR methods of the major house dust mite allergen Der p 2. J Biol Chem 1997; 272: 26893-26898. (Pubitemid 27452638)
51. Asturias JA, Ibarrola I, Arilla MC, Vidal C, Ferrer A, Gamboa PM, Viñuela J, Sanz ML, Andreu C, Martínez A: Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009; 39: 1088-1098.
52. Hakkaart GA, Chapman MD, Aalberse RC, van Ree R: Immune-reactivity of recombinant isoforms of the major house dust mite allergen Der p 2. Clin Exp Allergy 1998; 28: 169-174. (Pubitemid 28137332)
53. Smith AM, Chapman MD: Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996; 33: 399-405. (Pubitemid 26191484)
54. Smith AM, Chapman MD, Taketomi EA, Platts-Mills TA, Sung SS: Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J Allergy Clin Immunol 1998; 101: 423-425. (Pubitemid 28146366)
55. van 't Hof W, Driedijk PC, van den Berg M, Beck-Sickinger AG, Jung G, Aalberse RC: Epitope mapping of the Dermatophagoides pteronyssinus house dust mite major allergen Der p II using overlapping synthetic peptides. Mol Immunol 1991; 28: 1225-1232.